Tremfya vs Sotyktu
A side-by-side look at two autoimmune medications advertised on TV. Informational only — not medical advice.
| US Tremfya | US Sotyktu | |
|---|---|---|
| Generic name | guselkumab | deucravacitinib |
| Drug class | IL-23 Inhibitor (Biologic) | TYK2 Inhibitor |
| Treats | Plaque psoriasis, psoriatic arthritis | Plaque psoriasis |
| Category | Autoimmune | Autoimmune |
| Manufacturer | Janssen | Bristol-Myers Squibb |
| Year approved | 2017 | 2022 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | $140M | $130M |
| Common side effects | Respiratory infections, Headache, Injection site reactions, Joint pain | Common cold symptoms, Increased infections, Cold sores, Mouth sores |
Frequently asked questions
Is Tremfya or Sotyktu better?
Neither is universally "better." Tremfya (guselkumab) and Sotyktu (deucravacitinib) are both used for autoimmune, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Tremfya and Sotyktu?
Tremfya is a IL-23 Inhibitor (Biologic) made by Janssen, while Sotyktu is a TYK2 Inhibitor made by Bristol-Myers Squibb. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Tremfya has the larger estimated TV advertising budget of the two.